Association between clinical symptoms and apolipoprotein A1 or apolipoprotein B levels is regulated by apolipoprotein E variant rs429358 in patients with chronic schizophrenia.
Apolipoprotein A1
Apolipoprotein B
Apolipoprotein E
Clinical symptoms
Schizophrenia
Journal
Annals of general psychiatry
ISSN: 1744-859X
Titre abrégé: Ann Gen Psychiatry
Pays: England
ID NLM: 101236515
Informations de publication
Date de publication:
20 Dec 2021
20 Dec 2021
Historique:
received:
20
09
2021
accepted:
30
11
2021
entrez:
21
12
2021
pubmed:
22
12
2021
medline:
22
12
2021
Statut:
epublish
Résumé
The apolipoprotein E (ApoE) gene polymorphisms are correlated with blood lipid levels and several neuropsychiatric symptoms. Therefore, this study aimed to examine whether the ApoE rs429358 affected the development and clinical symptoms of schizophrenia and to explore the relationship between apolipoproteins levels and clinical symptoms. The ApoE rs429358 was genotyped using a case-control design. The Positive and Negative Syndrome Scale (PANSS) was employed to evaluate the psychopathology of all patients. A total of 637 patients with schizophrenia and 467 healthy controls were recruited. We found no significant differences in the genotype and allele distribution between the patient and control groups. A significant correlation between PANSS negative symptoms and ApoA1 levels (p = 0.048) or ApoB levels (p = 0.001) was found in patients with schizophrenia, which was also confirmed by linear regression analyses (p = 0.048 vs. p = 0.001). Interestingly, only in the T homozygote group, ApoA1 and ApoB levels were predictors of the PANSS negative symptom score (p = 0.008 vs. p = 0.012), while in the C allele carrier group, no correlation was observed. This study found that the levels of ApoA1 and ApoB were negatively associated with negative symptoms of patients with schizophrenia. Furthermore, the association between ApoA1 or ApoB levels and psychopathology of schizophrenia was regulated by ApoE rs429358.
Sections du résumé
BACKGROUND
BACKGROUND
The apolipoprotein E (ApoE) gene polymorphisms are correlated with blood lipid levels and several neuropsychiatric symptoms. Therefore, this study aimed to examine whether the ApoE rs429358 affected the development and clinical symptoms of schizophrenia and to explore the relationship between apolipoproteins levels and clinical symptoms.
METHODS
METHODS
The ApoE rs429358 was genotyped using a case-control design. The Positive and Negative Syndrome Scale (PANSS) was employed to evaluate the psychopathology of all patients.
RESULTS
RESULTS
A total of 637 patients with schizophrenia and 467 healthy controls were recruited. We found no significant differences in the genotype and allele distribution between the patient and control groups. A significant correlation between PANSS negative symptoms and ApoA1 levels (p = 0.048) or ApoB levels (p = 0.001) was found in patients with schizophrenia, which was also confirmed by linear regression analyses (p = 0.048 vs. p = 0.001). Interestingly, only in the T homozygote group, ApoA1 and ApoB levels were predictors of the PANSS negative symptom score (p = 0.008 vs. p = 0.012), while in the C allele carrier group, no correlation was observed.
CONCLUSIONS
CONCLUSIONS
This study found that the levels of ApoA1 and ApoB were negatively associated with negative symptoms of patients with schizophrenia. Furthermore, the association between ApoA1 or ApoB levels and psychopathology of schizophrenia was regulated by ApoE rs429358.
Identifiants
pubmed: 34930329
doi: 10.1186/s12991-021-00376-w
pii: 10.1186/s12991-021-00376-w
pmc: PMC8686343
doi:
Types de publication
Journal Article
Langues
eng
Pagination
56Subventions
Organisme : National Natural Science Foundation of China
ID : 81371477
Organisme : Key R&D Program of Science and Technology Department of Hebei Province
ID : 172777223
Organisme : Government-funded Subsidy Project for Specialty Capacity-Building and Specialist Leaders
ID : 361014
Informations de copyright
© 2021. The Author(s).
Références
Prim Care Companion J Clin Psychiatry. 2004;6(Suppl 2):8-13
pubmed: 16001095
Asian J Psychiatr. 2014 Jun;9:36-40
pubmed: 24813034
Schizophr Bull. 2018 Oct 17;44(6):1195-1203
pubmed: 29762765
Cold Spring Harb Perspect Med. 2012 Mar;2(3):a006312
pubmed: 22393530
East Asian Arch Psychiatry. 2013 Mar;23(1):21-8
pubmed: 23535629
Proc Natl Acad Sci U S A. 1986 Nov;83(21):8102-6
pubmed: 3464945
Lancet. 2015 Aug 22;386(9995):743-800
pubmed: 26063472
J Psychiatr Res. 2013 Nov;47(11):1549-56
pubmed: 23953755
Transl Psychiatry. 2018 Nov 29;8(1):258
pubmed: 30498208
Schizophr Res Cogn. 2020 Nov 19;23:100193
pubmed: 33294393
Lancet Psychiatry. 2019 Mar;6(3):211-224
pubmed: 30792114
Schizophr Res. 2013 Oct;150(1):157-62
pubmed: 23998954
PLoS One. 2012;7(6):e34078
pubmed: 22701550
Int J Mol Sci. 2019 Aug 04;20(15):
pubmed: 31382686
J Neuropsychiatry Clin Neurosci. 2009 Fall;21(4):440-4
pubmed: 19996253
Aging (Albany NY). 2021 Jun 16;13(12):16353-16366
pubmed: 34135129
Mol Psychiatry. 2008 Dec;13(12):1118-28
pubmed: 17938634
Int J Neurosci. 2010 Jul;120(7):502-6
pubmed: 20583903
Schizophr Res. 2019 Apr;206:82-88
pubmed: 30584027
Arch Med Sci. 2015 Aug 12;11(4):869-76
pubmed: 26322100
PLoS One. 2018 Apr 12;13(4):e0195687
pubmed: 29649252
Lancet Psychiatry. 2017 Apr;4(4):295-301
pubmed: 28237639
BMC Neurosci. 2018 Apr 19;19(Suppl 1):16
pubmed: 29745836
J Clin Psychiatry. 2003 Jun;64(6):663-7
pubmed: 12823080
Asian J Psychiatr. 2021 Dec;66:102877
pubmed: 34638091
Nat Neurosci. 2003 Apr;6(4):345-51
pubmed: 12658281
Popul Health Metr. 2010 Aug 17;8:24
pubmed: 20712909
Front Neurol. 2019 May 27;10:552
pubmed: 31191441
J Am Heart Assoc. 2019 Jun 4;8(11):e011433
pubmed: 31137992
Shanghai Arch Psychiatry. 2018 Jun 25;30(3):178-187
pubmed: 30858669
Eur Neuropsychopharmacol. 1998 Feb;8(1):55-66
pubmed: 9452941
Medicine (Baltimore). 2016 Dec;95(50):e5639
pubmed: 27977609
Exp Ther Med. 2017 Apr;13(4):1337-1342
pubmed: 28413474
Int J Alzheimers Dis. 2011 Apr 07;2011:721457
pubmed: 21559196
J Neural Transm (Vienna). 2017 Jul;124(7):891-897
pubmed: 28421313
Schizophr Bull. 1987;13(2):261-76
pubmed: 3616518
Front Aging Neurosci. 2014 Jul 08;6:154
pubmed: 25071563
PLoS Med. 2005 May;2(5):e141
pubmed: 15916472
Neurosci Bull. 2016 Aug;32(4):383-8
pubmed: 27017941
Neurosci Lett. 2006 Nov 6;408(1):68-72
pubmed: 16997467
Mol Psychiatry. 2001 May;6(3):307-10
pubmed: 11326299
Acta Pharmacol Sin. 2003 Oct;24(10):1001-5
pubmed: 14531942
Schizophr Res. 2003 Aug 1;62(3):225-30
pubmed: 12837518
Schizophr Res. 2006 Jan 31;81(2-3):291-300
pubmed: 16309894
Circulation. 2019 Mar 19;139(12):1472-1482
pubmed: 30667276
Am J Med Genet B Neuropsychiatr Genet. 2003 May 15;119B(1):18-23
pubmed: 12707932
Schizophr Bull. 2015 Jan;41(1):154-62
pubmed: 24907239
Am J Epidemiol. 2002 Mar 15;155(6):487-95
pubmed: 11882522
Proc Nutr Soc. 2012 Aug;71(3):410-24
pubmed: 22564824
J Cell Mol Med. 2012 Jun;16(6):1184-95
pubmed: 22304330
Neuropsychiatr Dis Treat. 2016 Feb 16;12:357-73
pubmed: 26937191
EBioMedicine. 2020 Sep;59:102954
pubmed: 32818802
Am J Psychiatry. 2004 Feb;161(2 Suppl):1-56
pubmed: 15000267
Lancet. 1997 Sep 27;350(9082):930-1
pubmed: 9314875
Mol Biotechnol. 2004 Feb;26(2):147-64
pubmed: 14764940
Immunogenetics. 2006 Apr;58(2-3):113-21
pubmed: 16547745
Bioinformatics. 2006 Aug 1;22(15):1928-9
pubmed: 16720584
Am J Phys Anthropol. 2010 Sep;143(1):100-11
pubmed: 20734437
Ageing Res Rev. 2012 Jan;11(1):87-103
pubmed: 21763789
Mol Neuropsychiatry. 2019 Mar;5(1):52-59
pubmed: 31019918
Am J Med Genet B Neuropsychiatr Genet. 2018 Mar;177(2):126-142
pubmed: 27943569
PLoS One. 2014 Dec 12;9(12):e114618
pubmed: 25502880
PLoS One. 2017 Oct 18;12(10):e0186196
pubmed: 29045483
J Lipids. 2017;2017:8236325
pubmed: 28473926
Bull World Health Organ. 2008 Aug;86(8):650-2
pubmed: 18797627
Curr Alzheimer Res. 2010 Mar;7(2):158-64
pubmed: 19715553
Schizophr Res. 2015 Dec;169(1-3):355-368
pubmed: 26372448
World J Biol Psychiatry. 2010 Aug;11(5):719-28
pubmed: 20446881
Lancet Psychiatry. 2020 Jan;7(1):64-77
pubmed: 31860457
Heliyon. 2019 Jul 03;5(7):e02033
pubmed: 31317083